Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

7792 ARTÍCULOS , VIENDO DEL 4111 AL 4125

Derailed degradation: LRRK2-dependent exocytosis in Parkinson's disease

Ferguson SM.

Proc Natl Acad Sci U S A. 2025 Aug 12;122(32):e2515758122. doi: 10.1073/pnas.2515758122. Epub 2025 Aug 4.

Targeting the Dectin-1 Receptor in Neuroinflammation: Therapeutic Implications for Neuropsychiatric Disorders

Nascimento EFD, Batista PVC, Cunha CS, Lacerda LRA, Moura VC, Oliveira TQ, Filho AJMC, de Rezende PHF, Macedo DS, Vasconcelos SMM.

ACS Chem Neurosci. 2025 Aug 20;16(16):3082-3095. doi: 10.1021/acschemneuro.5c00221. Epub 2025 Aug 4.

The Role of Gut-Brain Axis in Modulating the Impact of Sterile Inflammation on Neuroimmune Responses in Neurodegenerative Diseases - Alzheimer's Disease and Parkinson's Disease

Ling PZ, Wong KH, Ho YS, Cheng WY, Chang RC.

Neuroimmunomodulation. 2025 Aug 4:1-22. doi: 10.1159/000547746. Online ahead of print.

Spinal cord stimulation restores locomotion in a Parkinson's disease patient and rodents

Slack JC, Rees B, Borda E, Slack J, Nicolelis MAL, Zauber SE, Gupta K, Yadav AP.

Brain Stimul. 2025 Sep-Oct;18(5):1407-1422. doi: 10.1016/j.brs.2025.07.020. Epub 2025 Aug 5.

Metformin as a potential neuroprotective agent that influence Parkinson's disease

Pal B, Ghatak N, Hossain CM.

Neurol Sci. 2025 Oct;46(10):4805-4818. doi: 10.1007/s10072-025-08370-w. Epub 2025 Aug 4.

DBS-STN&SNr combined stimulation versus DBS-STN monotarget stimulation for Parkinson's disease freezing: A comparative efficacy study

Tan B, Chen T, Guo P, Song P, Lin F, He S, Sun S, Wang X, He J, Yin X.

J Parkinsons Dis. 2025 Nov;15(7):1264-1274. doi: 10.1177/1877718X251359241. Epub 2025 Aug 4.

[Effect of uric acid on the progression of Parkinson's disease: Myth or reality?]

Yusupov FA, Yuldashev AA, Abdykadyrov MS, Yusupova TF.

Zh Nevrol Psikhiatr Im S S Korsakova. 2025;125(7):7-14. doi: 10.17116/jnevro20251250717.

[Sporadic form of Guam disease (ALS-parkinsonism-dementia complex)]

Kicherova OA, Doyan YI, Kicherova KP, Reichert LI, Root VA.

Zh Nevrol Psikhiatr Im S S Korsakova. 2025;125(7):135-141. doi: 10.17116/jnevro2025125071135.

Searching Heterocyclic Scaffolds Used to Treat Alzheimer's Disease: A Review

Kale MA, Faisal M.

Curr Drug Res Rev. 2025;17(2):266-281. doi: 10.2174/0125899775290026240612104933.

Netrin-1: Dual Roles in Neuroinflammation and Neurodegenerative Disease Dynamics

Farahani H, Ganji A, Mosayebi G, Monfared ME, Ghazavi A.

Int J Inflam. 2025 Jul 28;2025:8670048. doi: 10.1155/ijin/8670048. eCollection 2025.

Appendectomy and risk of Parkinson's disease: a systematic review and meta-analysis

Chin HL, Tsang YS, Shi H.

Front Neurol. 2025 Jul 21;16:1619236. doi: 10.3389/fneur.2025.1619236. eCollection 2025.

Efficacy of cholinesterase inhibitors and memantine on symptoms not responsive to levodopa in patients affected by Parkinson's disease without dementia: a systematic review

Cani I, Grotteschi N, Calandra-Buonaura G, Guarino M, Guaraldi P, Giannini G, Baldelli L, Donati M, Cortelli P, Camerlingo MD, Nonino F, Sambati L.

BMJ Neurol Open. 2025 Aug 3;7(2):e001079. doi: 10.1136/bmjno-2025-001079. eCollection 2025.

Innovations in Parkinson's Disease: Strategies and Novel Technologies

Sha R, Dabus MA, Torres-Russotto DR, Bhakuni N, Dabus GC.

Cureus. 2025 Jul 5;17(7):e87309. doi: 10.7759/cureus.87309. eCollection 2025 Jul.

Antidiabetic drugs in Parkinson's disease: a comprehensive meta-analysis on efficacy and safety with trial sequential analysis and GRADE evaluation

Abou Elezz AM, Khalefa K, Gadelmawla AF, Khattab YA, Abo Zeid M.

Inflammopharmacology. 2025 Aug;33(8):4577-4593. doi: 10.1007/s10787-025-01873-0. Epub 2025 Aug 5.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias